ABSTRACT BACKGROUND: Although Ranson score is the most commonly used prognostic model in the severity of acute pancreatitis (AP), ischemia-modified albumin (IMA) has been reported as a novel biomarker of various ischemia-based diseases in recent years. The aim of the present study is to investigate the correlation between Ranson score and IMA in patients with AP.
To date, many single-parameter and multi-parameter indicators have been reported to predict AP severity. Among those, Ranson criteria are the most widely used grading model; however, the need of many complex parameters and 48 h after admission to obtain a basic predictive score are its main limitations. In this respect, ischemia-modified albumin (IMA), a well-known biomarker of ischemia-based diseases such as stroke, acute mesenteric ischemia, acute pulmonary embolism, and acute coronary syndrome, may be considered as a novel predictor AP severity. [1] [2] [3] [4] Apart from being an ischemic marker, IMA has been also reported to be an indicator of oxidative stress. [5] Although the main pathogenesis of AP is self-digestion of the organ by the abnormal activation of digestive enzymes, it was also shown that free oxygen radicals and cytokines have important roles in pancreatic damage and disease course. [6] In this study, we aimed to determine whether serum IMA can be used as a novel and alternative indicator for predicting AP severity.
INTRODUCTION
Acute pancreatitis (AP) is among the most common causes of acute abdominal emergencies in the world. Although most of the patients with AP have mild disease, approximately 15%-20% cases develop severe or necrotizing form of AP. It is well known that AP, particularly severe form, is associated with increased morbidity and mortality rates. Therefore, determining disease severity within the first hours after hospital admission is of great importance for both treatment planning and decreasing the morbidity and mortality.
MATERIALS AND METHODS

Patients and Study Design
Forty-three patients diagnosed with AP between December 2015 and April 2016 were included in this prospective clinical study. Patients with diabetes mellitus, chronic renal/hepatic failure, and cirrhosis as well as those aged <18 years were excluded from the study. The following criteria were used for the diagnosis of AP: acute onset of abdominal pain, typical physical examination findings, at least three-fold increase in plasma amylase level, and sonographic and/or tomographic confirmation of AP.
Plasma IMA level was measured after AP diagnosis and before treatment. Albumin cobalt binding calorimetric assay, previously described by Bar-Or et al., [7] was used for IMA measurements, and the results were provided in absorbance unit (ABSU). A formula (serum albumin concentration of the patient/median serum albumin concentration of the study population) × IMA ABSU value was used to eliminate the effect of albumin on IMA, and hence to obtain the corrected IMA.
All patients were classified as mild and severe AP, according to the Atlanta criteria based on the presence of organ failure for >48 h and/or local complications. [8] The criteria of organ failure were as follows: shock (systolic blood pressure <90 mmHg), renal failure (serum creatinine level >2 mg/dL after rehydration or hemodialysis), or pulmonary insufficiency (arterial PO2 <60 mmHg at room air or the need for mechanical ventilation). Ranson score was calculated using data in the first 24 h and after 48 h of admission.
Institutional Ethics Committee of Numune Training and Research Hospital approved this study. Written informed consent was obtained from all patients.
Statistical Analysis
Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, Illinois). Kolmogorov-Smirnov test was used to assess the normality of data distribution. The variables were presented as mean ± standard deviation (SD), median and interquartile range (IQ), or number and percentage unless otherwise specified. Chi-square test or Fisher exact test were used to compare categorical data, and Mann-Whitney U-test was used for the comparison of continuous variables. Correlations of IMA with amylase level, Ranson score, and disease severity were analyzed by Spearman's correlation coefficient. A p value of <0.05 was considered statistically significant.
RESULTS
A total of 43 patients with biliary AP were included in the study. There were 17 (39.5%) males and 26 (60.5%) females, with a mean age of 63.6 (22-90) years. The median length of hospital stay was 6.1 (3-12) days, and no mortality was observed during this period.
A total of 29 (67.4%) patients were diagnosed as mild AP. The remaining 14 (32.6%) patients had moderately severe or severe form of disease, and were classified as severe AP. The patients who had severe form of AP were older than those with mild AP (p=0.020). Ranson score was also higher in patients with severe AP than in those with mild disease (p=0.011). The mean IMA level was 0.626+0.11 (0.379-0.947) ABSU. The correlation between IMA level and amylase level, Ranson score, and disease severity (according to the Atlanta classification) was statistically evaluated. It was found that there was no correlation between IMA levels and amylase levels in the whole study population (rho=+0.116, p=0.470). IMA was also not found to be correlated with Ranson score (rho=−0.070, p=0.664). Similarly, no correlation was observed between IMA level and the disease severity (rho=0.053, p=0.741) (Fig. 1) .
DISCUSSION
Despite recent advances in diagnostic algorithms, critical care conditions, and other therapeutic approaches, AP, especially severe form of the disease, is still a dangerous disease with a mortality rate of 10%-20%. [9] Approximately half of the deaths are related to multiple organ failure within the first week of the attack while septic complications are mainly responsible for the delayed mortality. Because of the high morbidity and mortality rates in AP, many scoring systems, laboratory tests, and radiological methods have been recommended to estimate the clinical disease course. Some of those grading systems including Ranson, [10] Bedside Severity Index of AP (BISAP), [11] and Imrie/Glasgow [12] include parameters specific to AP whereas others, such as Acute Physiologic and Chronic Health Evaluation System (APACHE) [13] and the Mortality Probability Models (MPM) II [14] scores, are not specific to AP, and are widely used in all critically ill patients.
Apart from the complicated scoring systems, single biochemical markers such as C-reactive protein, procalcitonin, red cell distribution width, and interleukins have also been reported as promising predictors of AP severity. [15] [16] [17] However, none of those provide an accurate prediction of disease severity, and thus are not widely used in routine practice. In this regard, IMA, a well-known marker for various ischemic-based diseases, may be considered as a novel and alternative predictor of disease severity considering that poor antioxidant status has been shown to be associated with progression of complications in AP. [18, 19] It is known that various ischemic stressors are released from hypoxic tissues, and modify N-terminal amino acids of circulating albumin to a different subtype called as IMA. [20] This biochemical marker has been shown to play important roles in various hypoxic conditions, especially in ischemic heart disease. [2, 4, 21] Although the pathogenesis of AP is multifactorial, an increasing number of studies have focused on the relationship between the oxidative stress status and AP. [19, 22] Oxidative stress is primarily related to excessive production of reactive oxygen metabolites, which can cause damage in pancreatic cells. Free oxygen radicals are also considered to be involved in pancreatic edema and necrosis processes. [23, 24] Free oxygen radicals modify the metal binding terminals of human albumin. Therefore, the production of IMA is directly related to the production of free oxygen radicals. [25] In addition, IMA level raises within a few minutes after tissue injury caused by free oxygen radicals, and returns to normal serum level after 6-12 h.
To date, the diagnostic role of IMA in various acute abdominal emergencies has been studied in a number of clinical studies. [2, 26, 27] In one of those, serum levels of oxidative stress markers including IMA were found to be higher in patients with acute appendicitis than in healthy individuals. However, the authors found no correlation between the pathological extent of acute appendicitis and oxidative stress markers. [26] In another study, plasma IMA level was found to be significantly higher in acute mesenteric ischemia in comparison to the nonoccluded group, suggesting that IMA might have a diagnostic value in acute thromboembolic occlusion of mesenteric vessels. [2] In the literature, there are only two studies on the association between IMA and AP. [19, 28] One of those was an experimental study conducted in rats, which aimed to determine the potential role of IMA in AP. [28] Plasma IMA level was found to be significantly higher in rats with AP than in healthy rats. It was also shown that IMA was strongly correlated with serum amylase level, indicating that IMA could be considered as a novel diagnostic marker in AP. Moreover, the authors reported IMA as an additional marker to monitor inflammation during AP. The other study was conducted in patients with mild biliary and/or nonbiliary AP, and aimed to investigate the potential diagnostic role of oxidative status with using various oxidative stress parameters including IMA. [19] The primary outcome of the study was that IMA was significantly elevated in patients with AP in comparison to healthy cases. The authors also showed a positive correlation between IMA and amylase and lipase levels, similar to the study by Topalo- glu et al. [28] All those findings obtained from the two studies indicated the diagnostic IMA level in AP. However, the predictive IMA level was not clearly investigated. It is well known that the estimation of disease severity is important in AP management, considering the risk of dangerous complications. In contrast to those studies, the primary aim of the present study was to investigate the prognostic value of IMA in patients with AP. Therefore, there was no control group consisting of healthy patients. In addition, we found no significant association between IMA levels and amylase levels. With regard to this point, it should be stated here that all patients, except one, had a plasma IMA level >0.400 ABSU, which is generally considered as a reference level for ischemia. [29] In the present study, IMA did not also show a correlation with both Ranson score and the Atlanta classification for predicting disease course. In our opinion, our work is the first report on this topic. It should be also noted that the sample size in both the previous studies was lower than that in our study. Consequently, all the findings obtained from the present study showed that IMA does not have any prognostic and predictive value in AP.
This study has some limitations. First, the sample size was small, and the majority of patients had Ranson score <4, making the statistical analysis difficult. Second, the measurement of IMA was not repeated after the treatment because the study mainly focused on the predictive value of IMA. Therefore, the effect of IMA in the clinical progress of patients was not evaluated.
In conclusion, this study is the first report on the prognostic role of IMA in patients with AP. According to the results from the present study, IMA does not seem to be a useful marker in earlier prediction of disease severity in patients with AP. However, the results should be confirmed by larger cohort studies. Despite important disadvantages, Ranson score more accurately indicates disease severity in patients with AP.
